

REMARKS

This is in response to the Office Action mailed June 26, 2006 for the above identified application. With a five-month extension, this response is due on December 26, 2006. The Examiner has required restriction of the claims in the present application to one of the following inventions:

Group I: claims 1-6, and 16-32, drawn to a process of treating a disease state associated with vascular targeting comprising administering a combination of vascular targeting agent and an anti-hypertensive agent.

Group II: claims 33-53, drawn to a process of reducing the hypertensive effect of a vascular targeting agent comprising administering a combination of vascular targeting agent and an anti-hypertensive agent.

In response, Applicants hereby elect, without traverse, the invention of Group I.

The Examiner also required election of a single disclosed species from each group of vascular targeting agents and anti-hypertensive agents, and election of a single disclosed species from a disease state associated with vascular targeting. Accordingly, Applicants elect the following species: combretastatin as the vascular targeting agent, nitroglycerin as the anti-hypertensive agent, and neoplastic disease/cancer as the disease state associated with vascular targeting.

It is Applicants' understanding that this species election is for searching purposes only and upon a finding of allowability of the elected species, the remaining species will also be searched. It is Applicants' further understanding that under 35 U.S.C. §121, upon required election of a single species for prosecution on the merits, the claims will be restricted to said species if no generic claim is finally held allowable. Applicants further understand that upon the allowance of a generic claim, they will be entitled to consideration of claims to additional species which are written in dependent form or

otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. §1.141 *et seq.*

Applicants respectfully reserve the right to prosecute the non-elected claims and species in a continuation or divisional application and also respectfully reserve the right to traverse the Examiner's requirement of a restriction/election in a future response to the U.S. Patent and Trademark Office.

Claims 1-8 and 15-53 are currently pending in the case. Claims 9-14 have been canceled. Claims 6, 20, 23, 38, 44, and 47 have been amended. Support for the amendment to claims 6, 20, 23, 38, 44, and 47 can be found in the specification as filed, at page 7, line 17.

Applicants reserve the right to further prosecute the canceled subject matter in this or in another patent application. No new matter is added.

Applicants submit that the application is in condition for allowance, and such action is respectfully requested. No additional fees are believed due, but please charge any payments that may be due to Deposit Account No. 50-0311, reference 18217-515.

Should any questions or issues arise concerning the application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Naomi Biswas, Reg. No. 38,384
Attorneys for Applicants
c/o MINTZ LEVIN
Tel.: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623